Status:

RECRUITING

Artificial Intelligence to Measure Adherence to Oral Medication

Lead Sponsor:

Northwell Health

Collaborating Sponsors:

National Institute of Mental Health (NIMH)

Conditions:

First Episode Psychosis

Eligibility:

All Genders

15-40 years

Phase:

PHASE4

Brief Summary

The aims of this project is to use an artificial intelligence (AI) smartphone app to provide support for medication adherence by patients with first episode psychosis.

Detailed Description

The challenge of oral medication adherence in first-episode psychosis (as in any potentially chronic illness) is enormous, and numerous studies have linked non-adherence to increased rates of relapse/...

Eligibility Criteria

Inclusion

  • Enrolled in a CSC program
  • Prescribed an oral antipsychotic

Exclusion

  • none

Key Trial Info

Start Date :

November 20 2020

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 31 2024

Estimated Enrollment :

200 Patients enrolled

Trial Details

Trial ID

NCT04046497

Start Date

November 20 2020

End Date

December 31 2024

Last Update

September 19 2024

Active Locations (5)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (5 locations)

1

Citrus Health

Hialeah, Florida, United States, 33012

2

InterAct

Grand Rapids, Michigan, United States, 49503

3

InterAct of Michigan

Kalamazoo, Michigan, United States, 49007

4

Red Rock

Oklahoma City, Oklahoma, United States, 73105

Artificial Intelligence to Measure Adherence to Oral Medication | DecenTrialz